Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Canasa is a prescription rectal suppository containing 1000 mg of mesalamine, an aminosalicylate. It is used in adults for mildly to moderately active ulcerative proctitis. The suppository acts locally in the rectum and is administered once daily, preferably at bedtime. Treatment duration under current mesalamine suppository labeling is three to six weeks.
read more about canasa ...The precise mechanism of mesalamine in ulcerative proctitis is not fully defined. Mesalamine acts locally on inflamed rectal tissue and reduces inflammatory activity. Proposed actions involve reduced production of inflammatory arachidonic acid metabolites and changes in other inflammatory signaling pathways within the intestinal lining.
Canasa is used in adults with mildly to moderately active ulcerative proctitis. The suppository is designed for rectal administration and acts primarily at the affected site. Current labeling does not establish safety and efficacy beyond six weeks of treatment.
One 1000 mg suppository is inserted rectally once daily at bedtime for three to six weeks. The suppository should not be cut or broken. After insertion, it is retained for one to three hours or longer when possible. Kidney function is evaluated before treatment and periodically during therapy.
Serious concerns include kidney impairment, mesalamine-induced acute intolerance syndrome, hypersensitivity reactions, severe skin reactions, liver failure in people with liver disease, kidney stones, and intracranial hypertension. Symptoms such as worsening abdominal pain, bloody diarrhea, fever, severe rash, visual changes, or persistent headache call for medical evaluation.
Canasa treats mildly to moderately active ulcerative proctitis in adults.
The labeled regimen uses one 1000 mg rectal suppository once daily at bedtime.
No. Current mesalamine suppository labeling states that the suppository should not be cut or broken.
Yes. Kidney function is evaluated before treatment and periodically while mesalamine therapy continues.
5-Aminosalicylic Acid. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/5-aminosalicylic-acid. Date Accessed September 21, 2026.
CANASA (mesalamine) suppository. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89d91601-152b-4398-bebe-af1c023e9935. Date Accessed September 21, 2026.
DailyMed - MESALAMINE suppository. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73317da3-cba0-4106-9e88-79b0e2f642af. Date Accessed September 21, 2026.
FDALabel - CANASA (mesalamine). https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/916836. Date Accessed September 21, 2026.
Mesalamine Rectal. MedlinePlus. https://medlineplus.gov/druginfo/meds/a614021.html. Date Accessed September 21, 2026.